https://peptide.exchange/move/survodutide-cardiovascular-safety-synchronize-cvotPeptide Exchangeen2026-11-10T05:15:00.000ZSurvodutide cardiovascular safety holds in Phase 3 as stomach dropouts near one in five https://peptide.exchange/move/metavia-da-1726-obesityweek-posterPeptide Exchangeen2026-11-10T04:41:00.000ZMetaVia ObesityWeek poster on DA 1726 arrives with its data still unseen https://peptide.exchange/move/maritide-phase-3-trials-fewer-dosesPeptide Exchangeen2026-11-09T04:54:00.000ZMariTide Phase 3 trials fill up as Amgen pitches as few as four doses a year https://peptide.exchange/move/orforglipron-blood-pressure-attain-analysesPeptide Exchangeen2026-11-09T04:28:00.000ZOrforglipron blood pressure falls most in stage 2 hypertension in ATTAIN analyses https://peptide.exchange/move/glp-1-food-cravings-semaglutide-tirzepatide-pilotPeptide Exchangeen2026-11-09T03:54:00.000ZGLP 1 food cravings fall in a small Italian study of semaglutide and tirzepatide